Le Lézard
Classified in: Business
Subject: NEW PRODUCTS/SERVICES

USCIS Approves EB5 Capital's JF32 - Addison Row Project


WASHINGTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- EB5 Capital is thrilled to announce that its Addison Row (JF32) project was recently approved by the United States Citizenship and Immigration Services (USCIS).   This I-956F approval signifies that USCIS, the government agency that oversees EB-5 program compliance, has assessed, and verified the compliance of the EB-5 project.

Addison Row (JF32) is a five-story 327-unit apartment building located in Capitol Heights, Maryland, bordering Washington, DC. The development is currently under construction and is scheduled to be completed this summer. JF32 is one of EB5 Capital's 20 projects in the Washington, DC region.

"We are very happy for the investors who joined our Addison Row project," said Brian Ostar, President of EB5 Capital. "This project approval marks the first major milestone in their EB-5 immigration process and is an indicator that individual I-526E petitions should soon follow."

EB5 Capital remains dedicated to identifying and executing projects that not only meet the rigorous requirements of the EB-5 Program but also contribute meaningfully to local communities and economies. Our team will continue to carefully track USCIS' petition approvals in Addison Row (JF32) and attentively monitor the remainder of the construction process while keeping our investors fully informed.

About EB5 Capital

EB5 Capital provides qualified foreign investors opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). As one of the country's oldest and most active Regional Center operators, the firm has raised more than one billion dollars of foreign capital across nearly 40 EB-5 projects. Headquartered in Washington, DC, EB5 Capital's distinguished track record and leadership in the industry has attracted investors from over 70 countries. Please visit www.eb5capital.com for more information.

Contact:
Katherine Willis
Director, Marketing & Communications
[email protected]



These press releases may also interest you

at 19:05
Vistra Set to Join S&P 500; Aaon to Join S&P MidCap 400; Marathon Digital Holdings to Join S&P SmallCap 600
S&P MidCap 400 constituent Vistra Corp. will replace Pioneer Natural Resources Co. in the S&P 500, S&P SmallCap 600 constituent Aaon Inc. (NASD: AAON) will replace Vistra in the S&P MidCap 400, and Marathon Digital Holdings Inc. (NASD: MARA) will...

at 19:00
VIZSLA SILVER PROVIDES FURTHER UPDATE ON ACQUISITION OF LARGE CLAIM PACKAGE ALONG HIGHLY PROSPECTIVE STRUCTURAL TREND, SOUTH OF PANUCO
Vizsla Silver Corp. ("Vizsla Silver" or the "Company") is pleased to announce that it has now issued 448,137 common shares (the "Consideration Shares") for the previously announced asset purchase agreement (the "Acquisition Agreement") dated March...

at 18:56
Frontenac Mortgage Investment Corporation Announces Filing of Amended and Restated Quarterly Financial Statements
Frontenac Mortgage Investment Corporation ("FMIC") announces that it has filed amended and restated interim unaudited financial statements and related management's discussion and analysis ("MD&A") for the quarters ended March 31, 2023, June 30, 2023...

at 18:16
CAPITAL COMMUNITY BANK ANNOUNCES THE ACQUISITION OF SECURITY HOME MORTGAGE
Capital Community Bank (CCBank), a leader in Utah community banking, is excited to announce the successful acquisition of Security Home Mortgage (SHM), a well-respected provider of home mortgage solutions since 1999. This landmark deal marks a...

at 18:05
Stellus Capital Investment Corporation Schedules First Quarter 2024 Financial Results Conference Call
Stellus Capital Investment Corporation will release its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024, after the close of the stock market....

at 18:00
BetterLife Announces Intent to Complete Private Placement of Units
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...

More news about Business...


News published on and distributed by: